| Name | Title | Contact Details |
|---|
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.
Mohawk Valley Health System is an integrated healthcare delivery system which includes St. Elizabeth Medical Center and Faxton St. Luke`s Healthcare, serving Oneida, Herkimer and Madison counties. We offer inpatient, primary, multi-specialty and long-term care. Services also include bariatric surgery, maternal child services, stroke care, surgical services, orthopedic services, cancer care, dialysis, diabetes program, rehabilitation, home care, cardiac care, imaging, wound care, emergency services, urgent care, outpatient laboratory services and more.
Hand Surgery Associates is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Denver, CO. To find more information about Hand Surgery Associates, please visit www.hsacolorado.com
Broadcast Med is a West Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.